Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary (GA) to Age-Related Macular Degeneration (AMD)

Trial Profile

A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary (GA) to Age-Related Macular Degeneration (AMD)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs IONIS FB LRX (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 23 Oct 2018 Planned End Date changed from 28 Feb 2021 to 10 Oct 2018.
    • 23 Oct 2018 Planned primary completion date changed from 1 Dec 2020 to 10 Oct 2018.
    • 23 Oct 2018 Status changed from recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top